REGENXBIO Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RGNX research report →
Companywww.regenxbio.com
REGENXBIO Inc. , a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.
- CEO
- Curran Simpson
- IPO
- 2015
- Employees
- 353
- HQ
- Rockville, MD, US
Price Chart
Valuation
- Market Cap
- $293.13M
- P/E
- -1.03
- P/S
- 3.34
- P/B
- 14.10
- EV/EBITDA
- -1.48
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -0.14%
- Op Margin
- -292.28%
- Net Margin
- -330.23%
- ROE
- -232.50%
- ROIC
- -92.12%
Growth & Income
- Revenue
- $170.44M · 104.54%
- Net Income
- $-193,878,000 · 14.63%
- EPS
- $-3.76 · 18.08%
- Op Income
- $-161,198,000
- FCF YoY
- 28.02%
Performance & Tape
- 52W High
- $16.19
- 52W Low
- $5.46
- 50D MA
- $8.73
- 200D MA
- $10.53
- Beta
- 1.12
- Avg Volume
- 1.09M
Get TickerSpark's AI analysis on RGNX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 11, 26 | PAKOLA STEVE | sell | 15,309 |
| Mar 10, 26 | PAKOLA STEVE | sell | 5,124 |
| Feb 1, 26 | Christmas Patrick J. | other | 4,700 |
| Feb 1, 26 | PAKOLA STEVE | other | 5,267 |
| Jan 27, 26 | Mills Kenneth T. | other | 225,000 |
| Jan 27, 26 | Mills Kenneth T. | other | 221,753 |
| Jan 27, 26 | Mills Kenneth T. | other | 225,000 |
| Jan 6, 26 | PAKOLA STEVE | other | 65,847 |
| Jan 6, 26 | PAKOLA STEVE | other | 35,402 |
| Jan 6, 26 | Malzahn Craig | other | 65,847 |
Our RGNX Coverage
We haven't published any research on RGNX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate RGNX Report →